Neil Woodford eyes 10%-plus annual returns with investment trust launch

clock

Woodford Investment Management (WIM) is seeking to raise an initial £200m for the launch of the Woodford Patient Capital investment trust, a portfolio of 50-100 quoted and unquoted businesses.

Contrary to speculation that manager Neil Woodford’s second offering at WIM would focus wholly on biotechnology companies, the trust will invest broadly in firms with “outstanding” intellectual property, including those higher up the cap scale. Early-stage investments, which are eventually expected to constitute 75% of the portfolio, will centre on areas including medical science and “disruptive” alternative finance firms. Aimed at investors with a five-year time horizon, the trust will charge no management fee, instead levying a performance fee that will be payable in ordinary shares...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment Trusts

Investment trusts close 2023 with 4.6% performance boost

Investment trusts close 2023 with 4.6% performance boost

Numis research into investment company universe

Cristian Angeloni
clock 04 January 2024 • 3 min read
What Q1 2023 and beyond could hold in store for markets

What Q1 2023 and beyond could hold in store for markets

Look at the road ahead, not the flies hitting the windscreen

Andrew Bell
clock 22 December 2022 • 8 min read
Fundsmith Emerging Equities trust proposes liquidation

Fundsmith Emerging Equities trust proposes liquidation

£323m Fundsmith Emerging Equities trust performance ‘fallen below expectations’

James Baxter-Derrington
clock 14 September 2022 • 1 min read